Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys
| Autor: | Hadley Mouhsine, Caroline Bouchez, Rojo Ratsimandresy, Jean-François Zagury, Lucille Desallais, Françoise Quintin-Colonna, Matthieu Montes, Gabriel Moreau, Hervé Do |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.drug_class Active immunization Monoclonal antibody Article 03 medical and health sciences 0302 clinical medicine Hypersensitivity Medicine Animals Humans Multidisciplinary biology business.industry Interleukin-6 Immunogenicity Antibodies Monoclonal Antibodies Neutralizing Receptors Interleukin-6 Hypersensitivity reaction Macaca fascicularis 030104 developmental biology Immunization Tetanus vaccine 030220 oncology & carcinogenesis Immunology Antibody Formation biology.protein Anti-IL-6 Antibody business Peptides medicine.drug |
| Zdroj: | Scientific Reports |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/srep19549 |
| Popis: | Interleukin-6 (IL-6) overproduction has been involved in the pathogenesis of several chronic inflammatory diseases and the administration of an anti-IL-6 receptor monoclonal antibody has been proven clinically efficient to treat them. However, the drawbacks of monoclonal antibodies have led our group to develop an innovative anti-IL-6 strategy using a peptide-based active immunization. This approach has previously shown its efficacy in a mouse model of systemic sclerosis. Here the safety, immunogenicity and efficacy of this strategy was assessed in non human primates. No unscheduled death and clinical signs of toxicity was observed during the study. Furthermore, the cynomolgus monkeys immunized against the IL-6 peptide produced high levels of anti-IL-6 antibodies as well as neutralizing antibodies compared to control groups. They also showed an important decrease of the cumulative inflammatory score following a delayed-type hypersensitivity reaction induced by the Tetanus vaccine compared to control groups (minus 57,9%, P = 0.014). These findings are highly significant because the immunizing IL-6 peptide used in this study is identical in humans and in monkeys and this novel anti-IL-6 strategy could thus represent a promising alternative to monoclonal antibodies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|